Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia.

Hdl Handle:
http://hdl.handle.net/10144/19977
Title:
Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia.
Authors:
Ferradini, L; Laureillard, D; Prak, N; Ngeth, C; Fernandez, M; Pinoges, L; Puertas, G; Taburet, A; Ly, N; Rouzioux, C; Balkan, S; Quillet, C; Delfraissy, J F
Journal:
AIDS
Abstract:
OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions. We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia. METHODS: Adults who started HAART 24 +/- 2 months ago were included. Plasma HIV-RNA levels were assessed by real-time polymerase chain reaction. Factors associated with virological failure were analysed using logistic regression. RESULTS: Of 416 patients, 59.2% were men; the median age was 33.6 years. At baseline, 95.2% were ART naive, 48.9% were at WHO stage IV, and 41.6% had a body mass index less than 18 kg/m. The median CD4 cell count was 11 cells/microl. A stavudine-lamivudine-efavirenz-containing regimen was initiated predominantly (81.0%). At follow-up (median 23.8 months), 350 (84.1%) were still on HAART, 53 (12.7%) had died, six (1.4%) were transferred, and seven (1.7%) were lost to follow-up. Estimates of survival were 85.5% at 24 months. Of 346 tested patients, 259 (74.1%) had CD4 cell counts greater than 200 cells/microl and 306 (88.4%) had viral loads of less than 400 copies/ml. Factors associated with virological failure at 24 months were non-antiretroviral naive, an insufficient CD4 cell gain of less than 350 cells/microl or a low trough plasma ART concentration. In an intention-to-treat analysis, 73.6% of patients were successfully treated. CONCLUSION: Positive results after 2 years of advanced HIV further demonstrate the efficacy of HAART in the medium term in resource-limited settings.
Affiliation:
Epicentre, Paris, France. msffr.comed@online.com.kh
Issue Date:
12-Nov-2007
URI:
http://hdl.handle.net/10144/19977
DOI:
10.1097/QAD.0b013e32828cc8b7
PubMed ID:
18090277
Language:
en
ISSN:
0269-9370
Appears in Collections:
Mental Health

Full metadata record

DC FieldValue Language
dc.contributor.authorFerradini, L-
dc.contributor.authorLaureillard, D-
dc.contributor.authorPrak, N-
dc.contributor.authorNgeth, C-
dc.contributor.authorFernandez, M-
dc.contributor.authorPinoges, L-
dc.contributor.authorPuertas, G-
dc.contributor.authorTaburet, A-
dc.contributor.authorLy, N-
dc.contributor.authorRouzioux, C-
dc.contributor.authorBalkan, S-
dc.contributor.authorQuillet, C-
dc.contributor.authorDelfraissy, J F-
dc.date.accessioned2008-03-06T14:23:30Z-
dc.date.available2008-03-06T14:23:30Z-
dc.date.issued2007-11-12-
dc.identifier.citationPositive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia. 2007, 21 (17):2293-301 AIDS-
dc.identifier.issn0269-9370-
dc.identifier.pmid18090277-
dc.identifier.doi10.1097/QAD.0b013e32828cc8b7-
dc.identifier.urihttp://hdl.handle.net/10144/19977-
dc.description.abstractOBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions. We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia. METHODS: Adults who started HAART 24 +/- 2 months ago were included. Plasma HIV-RNA levels were assessed by real-time polymerase chain reaction. Factors associated with virological failure were analysed using logistic regression. RESULTS: Of 416 patients, 59.2% were men; the median age was 33.6 years. At baseline, 95.2% were ART naive, 48.9% were at WHO stage IV, and 41.6% had a body mass index less than 18 kg/m. The median CD4 cell count was 11 cells/microl. A stavudine-lamivudine-efavirenz-containing regimen was initiated predominantly (81.0%). At follow-up (median 23.8 months), 350 (84.1%) were still on HAART, 53 (12.7%) had died, six (1.4%) were transferred, and seven (1.7%) were lost to follow-up. Estimates of survival were 85.5% at 24 months. Of 346 tested patients, 259 (74.1%) had CD4 cell counts greater than 200 cells/microl and 306 (88.4%) had viral loads of less than 400 copies/ml. Factors associated with virological failure at 24 months were non-antiretroviral naive, an insufficient CD4 cell gain of less than 350 cells/microl or a low trough plasma ART concentration. In an intention-to-treat analysis, 73.6% of patients were successfully treated. CONCLUSION: Positive results after 2 years of advanced HIV further demonstrate the efficacy of HAART in the medium term in resource-limited settings.-
dc.language.isoen-
dc.rightsPublished by Wolters Kluwer Lippincott Williams & Wilkins - Archived on this site by kind permission Wolters Kluweren_GB
dc.titlePositive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia.-
dc.contributor.departmentEpicentre, Paris, France. msffr.comed@online.com.kh-
dc.identifier.journalAIDS-

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.